This study evaluated baseline symptoms and disease characteristics in pediatric patients prescribed dupilumab for EoE, factors affecting time to insurance approval, and pediatric patient response to dupilumab for EoE in the first year following dupilumab initiation. Median time to approval was 2 days versus 22 days if initially denied. Patients with dysphagia at baseline were less likely to be denied. Dupilumab demonstrated high rates of clinical, histological and endoscopic improvements.

This study evaluates health-system specialty pharmacy (HSSP) pharmacists' roles in medication discontinuations, switches, and dose changes, focusing on cost avoidance. HSSP pharmacists intervene to ensure safe and effective use of specialty medications, preventing unnecessary costs. Pharmacists successfully avoided $129,705 - $162,133 in direct costs through their interventions. These findings support the employment and role of pharmacists in HSSPs, extending beyond prescription filling.

This study evaluated patient-reported outcomes (PROs) and pharmacist interventions in patients serviced by VSP in various clinical conditions. In patients with MS specifically, we found that 98% of patients reported no adverse effects, 90% reported no missed doses, and 98% reported their medication worked "good" or "excellent." Pharmacist interventions were commonly related to adherence, safety monitoring, and adverse effects. PROs can be useful to drive meaningful pharmacist interventions.

The objective of this study was to assess the efficacy of abatacept, adalimumab, and etanercept in pediatric JIA patients through changes in the Physician’s Global Assessment (PGA). We found that the majority of patients saw an improvement in their PGA score. Adverse events were similar across all three biologics, and the most common reason for biologic discontinuation was lack of response to therapy.

This study evaluated the response to adalimumab dose intensification (defined as a change in adalimumab therapy with reinduction or an increase in dosing frequency) in pediatric patients with inflammatory bowel disease.